Janssen Pharmaceutica Nv

Yu-Kai Lee

Mark R Player

Daniel J Parks

Carl R Illig

Tianbao Lu

Sanath K Meegalla

Jinsheng Chen

Kenneth Jerome Wilson

Hui Huang

Wenxi Pan

Sharmila Patel

Wing S Cheung

William H Parsons

Scott L Dax

Mark Andrew Youngman

Thomas P Markotan

Raymond Joseph Patch

Kenneth M Wells

Michele C Jetter

Karen L Milkiewicz

Raul R Calvo

Tho V Thieu

Jian Liu

Michael Richard Brandt

Derek A Beauchamp

Raul L Calvo

Michael Brandt

Disclosed are compounds, compositions and methods for treating Type II diabetes and other disorders affected by activity of the enzyme PDE10a. Such compounds are represented by Formula (I) below, wherein R, R, L and Q are defined herein. 

PDE10a inhibitors for the treatment of type II diabetes

Disclosed are compounds, compositions and methods for treating Type II diabetes. Such compounds are represented by Formula (I) as follows: wherein R, R, L, and Q are defined herein.

PDE 10a inhibitors for the treatment of type II diabetes

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Benzimidazole modulators of VR1

The present invention is directed to novel compounds of Formula I: and forms and pharmaceutical compositions thereof, and the use thereof as inhibitors of Factor Xa.

Factor Xa compounds

Growing community of inventors

Exton, PA, United States of America

Yu-Kai Lee